

1 **Impact of 26 Skin Diseases on the Risk of Non-Small**  
2 **Cell Lung Cancer: A Mendelian Randomization Study**  
3 **Using FinnGen R11 Data**

4 Xingyuan Li <sup>1</sup>

5 Hui Li <sup>2</sup>

6

7 <sup>1</sup>Hunan University of Chinese Medicine, Changsha, Hunan, China 410208;

8 <sup>2</sup>Hunan University of Chinese Medicine Affiliated Hospital of Changde, Changde,

9 Hunan, China 415000

10

11 Xingyuan Li <sup>1\*</sup>

12 Hui Li <sup>2\*</sup>

13 \*These authors contributed equally to this work

14

15 Correspondence: Hui Li

16 Hunan University of Chinese Medicine Affiliated Hospital of Changde, Changde,

17 Hunan, China **415000**

18 Email: [786802170@qq.com](mailto:786802170@qq.com)

19

20

21

22

23 **Abstract:**

24 **Purpose:** To determine whether genetic predisposition to various skin diseases influences the  
25 risk of non-small cell lung cancer (NSCLC) through Mendelian randomization (MR).

26 **Methods:** Single nucleotide polymorphisms (SNPs) associated with 26 skin diseases were  
27 extracted from the FinnGen R11 dataset and underwent rigorous quality control. To evaluate the  
28 association between these skin diseases and the risk of non-small cell lung cancer (NSCLC), we  
29 applied several analytical methods, including inverse-variance weighted (IVW), MR-Egger  
30 regression, weighted median, Simple mode, and Weighted mode. The robustness of the findings  
31 was further supported by assessing SNP heterogeneity with the Cochran Q test and evaluating  
32 horizontal pleiotropy using the MR-Egger intercept test.

33 **Results:** Our study revealed that genetically predicted dermatitis herpetiformis (DH) was  
34 significantly associated with an elevated risk of squamous cell carcinoma of the lung (SCC). Acne  
35 was nominally linked to an increased risk of SCC. Additionally, rhinophyma (RHN), hidradenitis  
36 suppurativa (HS), and DH were nominally associated with a higher risk of adenocarcinoma of the  
37 lung (ADC). Of the remaining 22 skin diseases analyzed, 7 lacked sufficient instrumental  
38 variables to meet inclusion criteria. The other 15 skin diseases showed no statistically significant  
39 association with NSCLC.

40 **Conclusion:** This study ultimately analyzed the relationship between 19 skin diseases and  
41 NSCLC at the genetic level, while 7 other skin diseases could not be analyzed due to insufficient  
42 instrumental variables. Dermatitis herpetiformis and acne were associated with an increased risk  
43 of squamous cell carcinoma of the lung. Additionally, rhinophyma, hidradenitis suppurativa, and  
44 dermatitis herpetiformis were associated with an increased risk of adenocarcinoma of the lung.

45 **Keywords:** [Skin Diseases, Genetic level, Non-Small Cell Lung Cancer, Mendelian  
46 randomization]

47 **1.Introduction**

48 Lung cancer is one of the most prevalent and deadly cancers worldwide<sup>[1]</sup>. Non-small  
49 cell lung cancer (NSCLC) accounts for about 85% of lung cancer cases, highlighting the

50 need for targeted research and therapies. The most common NSCLC subtypes are  
51 adenocarcinoma (ADC) and squamous cell carcinoma (SCC), representing 40% and 25-  
52 30% of cases, respectively <sup>[2]</sup>. The development and progression of NSCLC are  
53 influenced by genetic susceptibility, environmental factors, chronic inflammation, and  
54 immune system dysregulation <sup>[3]</sup>. Despite extensive research, the etiology and  
55 pathogenesis of lung cancer remain incompletely understood <sup>[4]</sup>.

56 Skin diseases are a group of conditions that affect the skin, hair, nails, and associated  
57 tissues. Several studies have already explored the physiological and pathological  
58 connections between the skin and lungs, particularly focusing on the shared roles of  
59 certain inflammatory pathways in lung and skin inflammation, as well as the relationship  
60 between inflammation and lung tumors <sup>[5]-[7]</sup> , However, there are still many deficiencies  
61 in the research on the correlation between specific skin diseases and lung diseases.

62 Previous Mendelian Randomization (MR) studies have also confirmed the association  
63 between psoriasis and the risk of lung cancer <sup>[8]-[9]</sup> , Additionally, a Mendelian  
64 randomization study demonstrated a relationship between psoriasis and pulmonary  
65 fibrosis <sup>[10]</sup>. Building on these studies, it is logical to further investigate the relationship  
66 between lung cancer and a broader range of skin diseases.

67 Based on current clinical practice, targeted therapy, immunotherapy, and radiotherapy for  
68 lung cancer often lead to varying degrees of adverse reactions in the skin and mucous  
69 membranes <sup>[10]-[11]</sup>. Therefore, in a clinical setting, it is challenging to accurately observe  
70 the relationship between skin diseases and lung cancer without these confounding factors.

71 The MR method uses genetic variants as instrumental variables to mitigate confounding  
72 factors and provide stronger evidence of causal relationships <sup>[12]</sup>. Unlike clinical trials,

73 MR can eliminate the influence of social environmental factors and treatment-related  
74 effects on study results <sup>[13]-[14]</sup>, making it an effective tool for studying the genetic links  
75 between skin diseases and lung cancer.

76

## 77 **2. Information and methodology**

### 78 ***2.1. Sources of information***

79 To utilize the most recent research data and ensure the uniformity of the study population, we  
80 chose to obtain the instrumental variables from the June 2024 R11 data of the FinnGen database  
81 ([index \(finngen.fi\)](#)). The final selected dataset is detailed in Table1.

### 82 ***2.2. Assumptions of the MR study***

83 The Mendelian Randomization (MR) study is grounded in three key assumptions that ensure valid  
84 causal inferences <sup>[15]</sup>. First, the relevance assumption requires that genetic instrumental variables  
85 (GIVs) are strongly associated with the exposure factors. Second, the independence assumption  
86 requires that GIVs are isolated from any confounders that might impact the correlation between  
87 GIVs and outcomes. Third, the exclusion restriction assumption mandates that GIVs influence  
88 outcomes solely through the exposure factors, with no direct impact on the outcomes themselves  
89 (Fig1). In this study, skin diseases are considered the primary exposure factors, with squamous  
90 cell carcinoma (SCC) and adenocarcinoma (ADC) of the lung as the outcomes of interest. The  
91 objective is to analyze the potential causal impact of skin diseases on these two major subtypes  
92 of non-small cell lung cancer (NSCLC).

### 93 ***2.3. Screening for genetic instrumental variables***

94 A stringent threshold of  $P < 5 \times 10^{-8}$  was used to identify single nucleotide polymorphisms  
95 (SNPs) significantly associated with exposure factors, qualifying them as genetic instrumental

96 variables (GIVs). This threshold selects only the most statistically significant SNPs, enhancing  
97 the reliability of the Mendelian Randomization (MR) analysis. To minimize confounding from  
98 linkage disequilibrium (LD), an  $r^2$  value of 0.001 and a genetic window of 10,000 kilobases (kb)  
99 were applied.

100 The strength of the GIVs was evaluated using the F statistic, calculated as  $F = (\text{beta}/\text{se})^2$ <sup>[16]</sup>. An F  
101 value below 10 indicates a weak instrumental variable, potentially compromising the MR analysis.  
102 Therefore, only SNPs with adequate F values were retained.

103 If the initial threshold of  $P < 5 \times 10^{-8}$  did not yield enough SNPs, it was relaxed to  $P < 5 \times 10^{-6}$ <sup>[17]</sup>  
104 to ensure sufficient genetic variants for analysis, especially for less common exposures. Despite  
105 this adjustment, 7 skin diseases still lacked enough instrumental variables and were excluded  
106 from the analysis.

## 107 **2. 4. Statistical analysis**

108 The study employed a range of advanced statistical methods, including Inverse Variance  
109 Weighted (IVW), MR-Egger regression, Weighted Median, Simple mode, and Weighted mode, to  
110 investigate the causal relationship between various skin diseases and non-small cell lung cancer  
111 (NSCLC). These methods provided a comprehensive analysis of potential genetic associations.  
112 The IVW method was used to estimate the overall causal effect by combining the effects of all  
113 selected SNPs, assuming no pleiotropy among genetic variants<sup>[18]</sup>. MR-Egger regression, by  
114 relaxing the no-pleiotropy assumption, accounted for possible biases by allowing some  
115 instrumental variables to influence the outcome through pathways other than the exposure<sup>[19]</sup>,  
116 The Weighted Median method, which requires that at least 50% of the total weight from genetic  
117 variants be valid<sup>[20]</sup>. The Simple mode method offered stable estimates when dealing with a small  
118 number of instrumental variables, while the Weighted mode method reduced bias caused by  
119 heterogeneous effects among genetic variants<sup>[21]</sup>. Cochran's Q test assessed heterogeneity  
120 among SNPs, with a  $P < 0.05$  indicating the presence of heterogeneity, suggesting that genetic  
121 variants may not be uniformly associated with the exposure or outcome. MR-Egger regression  
122 was also used to test for horizontal and directional pleiotropy, with SNPs causing significant

123 pleiotropy ( $P < 0.05$ ) being excluded to prevent bias [22]. Finally, A leave-one-out analysis was  
124 conducted to systematically exclude each SNP individually, assessing the influence of each on  
125 the overall association between exposure and outcome, ensuring no single SNP  
126 disproportionately influenced the results.

## 127 **Results**

### 128 ***3.1. Instrumental variable***

129 In the dataset of 26 skin diseases selected for this study, 7 datasets still could not obtain  
130 sufficient instrumental variables even after lowering the inclusion and exclusion criteria. For 9  
131 datasets, instrumental variables could only be obtained according to the reduced criterion of  $P <$   
132  $5 \times 10^{-6}$ . The remaining 10 datasets were able to obtain instrumental variables according to the  
133 general standard. Among these, the number of instrumental variables for the skin diseases that  
134 yielded positive results were as follows:

135 Dermatitis herpetiformis: 6

136 Acne: 5

137 Hidradenitis suppurativa: 3

138 Rhinophyma: 4

139 Notably, Rhinophyma could only obtain instrumental variables after lowering the significance  
140 threshold to  $P < 5 \times 10^{-6}$ , whereas the SNPs used for the other positive results all met the  
141 criteria before the reduction. The positive results of the MR analysis are presented in Table 3,  
142 while the heterogeneity and horizontal pleiotropy tests are shown in Table 2.

#### 143 **3.2.1. Dermatitis herpetiformis (DH) and NSCLC**

144 Mendelian Randomization (MR) analyses revealed a significant causal relationship between  
145 dermatitis herpetiformis (DH) and squamous cell carcinoma (SCC) of the lung. The analysis  
146 demonstrated robust associations with p-values: IVW  $P = 0.0782 \times 10^{-4}$ , MR-Egger  $P = 0.2778$ ,  
147 Weighted Median (WM)  $P = 0.0004$ , Simple mode  $P = 0.0845$ , and Weighted mode  $P = 0.0258$ .

148 No heterogeneity was detected (Cochran's Q test  $P > 0.05$ ), and the MR-Egger intercept test  
149 confirmed no significant pleiotropy ( $P = 0.6038$ ).  
150 For adenocarcinoma (ADC), the causal association with DH was weaker, reflected in p-values:  
151 IVW  $P = 0.0357$ , MR-Egger  $P = 0.2920$ , WM  $P = 0.0737$ , Simple mode  $P = 0.1908$ , and Weighted  
152 mode  $P = 0.1946$ . Cochran's Q test for ADC showed no heterogeneity ( $P > 0.05$ ), and the MR-  
153 Egger intercept test confirmed no significant pleiotropy ( $P = 0.6909$ ). Leave-one-out analysis  
154 confirmed that no single SNP disproportionately influenced the results. Scatter plots visually  
155 confirmed the consistency and direction of these findings across all methods. (Fig. 2).

### 156 **3.2.2. Acne (AC) and NSCLC**

157 Mendelian Randomization (MR) analyses indicated a specific association between acne (AC) and  
158 squamous cell carcinoma (SCC) of the lung. P-values across methods were: IVW  $P = 0.0321$ ,  
159 MR-Egger  $P = 0.2506$ , Weighted Median (WM)  $P = 0.0612$ , Simple mode  $P = 0.1997$ , and  
160 Weighted mode  $P = 0.1852$ . Cochran's Q test ( $P > 0.05$ ) confirmed no heterogeneity, and the  
161 MR-Egger intercept test ( $P = 0.4230$ ) showed no significant pleiotropy, supporting the reliability of  
162 this association.

163 No causal relationship was found between AC and adenocarcinoma (ADC) of the lung, with all  
164 methods yielding p-values greater than 0.05. Cochran's Q test ( $P > 0.05$ ) and MR-Egger intercept  
165 test ( $P = 0.8928$ ) confirmed no heterogeneity or pleiotropy, reinforcing the conclusion that AC is  
166 not related to ADC. Scatter plots visually depicted the causal relationship between AC and  
167 NSCLC (Fig. 3).

### 168 **3.2.3. Hidradenitis suppurativa (HS) and NSCLC**

169 Mendelian Randomization (MR) analysis indicated a causal relationship between hidradenitis  
170 suppurativa (HS) and lung adenocarcinoma (ADC), supported by p-values: IVW  $P = 0.0260$ , MR-  
171 Egger  $P = 0.5434$ , Weighted Median (WM)  $P = 0.0590$ , Simple mode  $P = 0.2014$ , and Weighted  
172 mode  $P = 0.2244$ . Cochran's Q test ( $P > 0.05$ ) indicated no heterogeneity, and the MR-Egger

173 intercept test ( $P = 0.7080$ ) showed no significant pleiotropy, confirming the reliability of the HS-  
174 ADC association.

175 No causal relationship was found between HS and squamous cell carcinoma (SCC) of the lung,  
176 with all methods yielding p-values greater than 0.05. The MR-Egger intercept test ( $P = 0.2834$ )  
177 confirmed no significant pleiotropy, though the IVW Q test for SCC showed heterogeneity ( $P =$   
178  $0.0062$ ). This heterogeneity is less concerning due to the overall negative results for SCC. Leave-  
179 one-out analysis identified a single SNP with significant impact, but removing it left only two  
180 instrumental variables, insufficient for robust analysis. Scatter plots visually depicted the causal  
181 relationship between HS and NSCLC (Fig. 4).

#### 182 **3.2.4. Rhinophyma (RHN) and NSCLC**

183 Mendelian Randomization (MR) analyses suggested a potential causal relationship between  
184 rhinophyma (RHN) and adenocarcinoma (ADC) of the lung, with p-values: IVW  $P = 0.0382$ , MR-  
185 Egger  $P = 0.7349$ , Weighted Median (WM)  $P = 0.1433$ , Simple mode  $P = 0.4288$ , and Weighted  
186 mode  $P = 0.2913$ . Cochran's Q test ( $P > 0.05$ ) indicated no significant heterogeneity, and the MR-  
187 Egger intercept test ( $P = 0.7095$ ) showed no significant pleiotropy. One SNP significantly  
188 impacted the results in the leave-one-out analysis, but only the IVW method retained a p-value  
189 below 0.05 after exclusion.

190 No causal relationship was found between RHN and squamous cell carcinoma (SCC), with all  
191 methods yielding p-values greater than 0.05. Cochran's Q test ( $P > 0.05$ ) and MR-Egger test ( $P =$   
192  $0.4915$ ) confirmed no heterogeneity or pleiotropy. Scatter plots illustrated these relationships (Fig.  
193 5). The association between RHN and ADC should be interpreted with caution due to the reliance  
194 on a lowered significance threshold.

#### 195 **3.2.5. The remaining 15 skin conditions and NSCLC**

196 The remaining 15 skin conditions showed no association with the two types of NSCLC (all  
197 analysis methods  $P > 0.05$ ). For datasets where the leave-one-out analysis revealed that certain  
198 SNPs interfered with the results, a new MR analysis was performed after removing the



199 corresponding SNPs. The analysis conducted after removing the corresponding SNPs still failed  
200 to yield positive results.

## 201 Discussion

202 In modern life sciences research, both the lungs and the skin originate from the mesoderm,  
203 indicating a shared homology in their growth and development <sup>[23]-[24]</sup>. Pathophysiological studies  
204 have further confirmed the connection between the two. For example, in mucosal immunity,  
205 secretory immunoglobulin A (sIgA) serves as a key effector molecule. Research has shown its  
206 varying levels of expression in diseases such as asthma and chronic urticaria <sup>[25][26]</sup>. Some studies  
207 focusing on the relationship between immunity, inflammation, and malignancy have identified key  
208 pathways, including Toll-like receptors (TLRs) and the tumor microenvironment (TME), which  
209 share inflammatory signals with skin diseases. For instance, cytokines such as TNF- $\alpha$ , IL-6, and  
210 IL-1 $\beta$  play critical roles in both lung and skin inflammation, suggesting that there may be  
211 mechanistic overlaps between pulmonary and dermatological conditions <sup>[6]</sup>. In NSCLC, commonly  
212 used EGFR-TKI targeted drugs frequently cause skin rashes as the most common side effect.  
213 Current research on EGFR-TKI-related rashes suggests that the primary cause of these rashes is  
214 the disruption of the EGFR pathway, leading to interference with keratinocyte growth, migration,  
215 proliferation, and differentiation <sup>[27]</sup>.

216 Recent MR studies on psoriasis and lung cancer published over the past two years <sup>[8]-[9]</sup> have  
217 bolstered our confidence in exploring this area further. Consequently, our team, building on these  
218 studies and leveraging the updated FinnGen R11 dataset from June 2024, selected 26 skin  
219 diseases as instrumental variables to investigate the relationship between skin diseases and non-  
220 small cell lung cancer.

221 Regarding the four skin diseases that yielded positive results: Dermatitis herpetiformis, Acne,  
222 Hidradenitis suppurativa, and Rhinophyma.

223 Dermatitis herpetiformis (DH) is characterized by blistering rashes, often accompanied by intense  
224 itching, and frequently co-occurs with celiac disease. Previous studies have identified a significant  
225 association between DH and the development of malignancies. A 2012 cohort study, with a 25-

226 year follow-up, concluded that DH was significantly linked to the incidence of visceral and  
227 lymphatic tumors [28]-[29]. However, few further in-depth studies have been conducted on this topic  
228 since then.

229 For Acne, there are a few reports linking it with malignancies such as breast cancer and prostate  
230 cancer. However, no other studies have clearly elucidated the relationship between Acne and  
231 lung cancer [30]-[31].

232 Hidradenitis suppurativa (HS) has been associated with lymphoma [32] and skin malignancies in  
233 previous studies. Approximately 0.5% to 4.6% of HS patients have later been diagnosed with  
234 cutaneous squamous cell carcinoma [33]. Additionally, a systematic review encompassing 2,795  
235 articles demonstrated an association between HS and psoriasis, indicating shared inflammatory  
236 pathways such as the IL-12-IL-23 axis, IL-17 interactions, and tumor necrosis factor (TNF)- $\alpha$  [34].  
237 Previous studies have confirmed the association between psoriasis and the risk of lung cancer [8]-  
238 [9]. Therefore, the correlation between HS and NSCLC is supported by existing research.

239 Rhinophyma is generally considered an advanced manifestation of Rosacea. Currently, research  
240 specifically on Rhinophyma is limited, but studies on Rosacea have confirmed its association with  
241 an increased risk of skin and breast malignancies, particularly showing a significant correlation  
242 with HER2-negative breast cancer [35]-[36].

243 The MR analysis provides new evidence on the relationship between four skin diseases  
244 (Dermatitis herpetiformis, Acne, Rhinophyma, and Hidradenitis suppurativa) and the risk of  
245 NSCLC. However, the study has limitations, To ensure the consistency of the study population,  
246 we can currently only choose data with a predominantly European population. Additionally,  
247 although the causal relationships were analyzed using genetic instrumental variables, the results  
248 show that, apart from Dermatitis herpetiformis, the other three skin diseases are only associated  
249 with one type of NSCLC. Further research is needed to understand the specific relationships and  
250 patterns between different skin diseases and NSCLC subtypes. In addition, after the relevant  
251 genomic studies are further refined, further studies in Asian populations are needed to compare  
252 the results with the present study.

253

## 254 **Conclusion**

255 This study confirms the association between four skin diseases and the risk of NSCLC. Dermatitis  
256 herpetiformis is significantly associated with an increased risk of squamous cell carcinoma of the  
257 lung. Acne shows a nominal association with an increased risk of squamous cell carcinoma of the  
258 lung. Rhinophyma, Hidradenitis suppurativa, and Dermatitis herpetiformis also exhibit nominal  
259 associations with an increased risk of adenocarcinoma of the lung. These findings provide  
260 direction for future clinical and experimental research related to NSCLC and highlight the  
261 importance of NSCLC screening and prevention in patients with these conditions. The fifteen skin  
262 diseases not found to be associated with NSCLC can help guide future research away from  
263 unrelated areas. Further genomic studies are necessary for the seven skin diseases for which  
264 sufficient SNP data were not obtained.

## 265 **Acknowledgments**

266 We thank FinnGen database for their contributions.

## 267 **Data availability**

268 The dataset in this study can be found in the FinnGen database.

## 269 **Consent for publication**

270 Not applicable.

## 271 **Funding**

272 This study was partially supported by the 2024 Traditional Chinese Medicine Research Program  
273 of Hunan Provincial Administration of Traditional Chinese Medicine (Grant Number: D2024032).

## 274 Competing interests

275 The author(s) report no conflicts of interest in this work.

## 276 References

- 277 [1] Ganti AK, Klein AB, Cotala I, Seal B, Chou E. Update of Incidence, Prevalence, Survival, and  
278 Initial Treatment in Patients With Non-Small Cell Lung Cancer in the US. *JAMA Oncol.* 2021  
279 Dec 1;7(12):1824-1832. doi: 10.1001/jamaoncol.2021.4932. PMID: 34673888; PMCID:  
280 PMC8532041.
- 281 [2] Araghi M, Mannani R, Heidarnejad Maleki A, Hamidi A, Rostami S, Safa SH, Faramarzi F,  
282 Khorasani S, Alimohammadi M, Tahmasebi S, Akhavan-Sigari R. Recent advances in non-  
283 small cell lung cancer targeted therapy; an update review. *Cancer Cell Int.* 2023 Aug  
284 11;23(1):162. doi: 10.1186/s12935-023-02990-y. PMID: 37568193; PMCID: PMC10416536.
- 285 [3] Rodak O, Peris-Díaz MD, Olbromski M, Podhorska-Okolów M, Dzięgiel P. Current Landscape  
286 of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies,  
287 and Immunotherapy. *Cancers (Basel).* 2021 Sep 20;13(18):4705. doi:  
288 10.3390/cancers13184705. PMID: 34572931; PMCID: PMC8470525.
- 289 [4] Czarnowicki T, Krueger JG, Guttman-Yassky E. Novel concepts of prevention and treatment  
290 of atopic dermatitis through barrier and immune manipulations with implications for the atopic  
291 march. *J Allergy Clin Immunol.* 2017 Jun;139(6):1723-1734. doi: 10.1016/j.jaci.2017.04.004.  
292 PMID: 28583445.
- 293 [5] Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer.  
294 *J Clin Invest.* 2007 May;117(5):1175-83. doi: 10.1172/JCI31537. PMID: 17476347; PMCID:  
295 PMC1857251.
- 296 [6] Subudhi I, Konieczny P, Prystupa A, Castillo RL, Sze-Tu E, Xing Y, Rosenblum D, Reznikov I,  
297 Sidhu I, Loomis C, Lu CP, Anandasabapathy N, Suárez-Fariñas M, Gudjonsson JE, Tsirigos  
298 A, Scher JU, Naik S. Metabolic coordination between skin epithelium and type 17 immunity  
299 sustains chronic skin inflammation. *Immunity.* 2024 Jul 9;57(7):1665-1680.e7. doi:  
300 10.1016/j.immuni.2024.04.022. Epub 2024 May 20. PMID: 38772365; PMCID: PMC11236527.
- 301 [7] Budisan L, Zanoaga O, Braicu C, Pirlóg R, Covaliu B, Esanu V, Korban SS, Berindan-Neagoe  
302 I. Links between Infections, Lung Cancer, and the Immune System. *Int J Mol Sci.* 2021 Aug  
303 30;22(17):9394. doi: 10.3390/ijms22179394. PMID: 34502312; PMCID: PMC8431665.
- 304 [8] Luo Q, Chen J, Qin L, Luo Y, Zhang Y, Yang X, Wang H. Psoriasis may increase the risk of  
305 lung cancer: a two-sample Mendelian randomization study. *J Eur Acad Dermatol Venereol.*  
306 2022 Nov;36(11):2113-2119. doi: 10.1111/jdv.18437. Epub 2022 Jul 28. PMID: 35844064.
- 307 [9] Wang X, Wang X, Wang H, Yang M, Dong W, Shao D. Association between psoriasis and lung  
308 cancer: two-sample Mendelian randomization analyses. *BMC Pulm Med.* 2023 Jan 5;23(1):4.  
309 doi: 10.1186/s12890-022-02297-0. PMID: 36604675; PMCID: PMC9814449.
- 310 [10] Fyhrquist N, Muirhead G, Prast-Nielsen S, Jeanmougin M, Olah P, Skoog T, Jules-Clement G,  
311 Feld M, Barrientos-Somarribas M, Sinkko H, van den Bogaard EH, Zeeuwen PLJM, Rikken G,  
312 Schalkwijk J, Niehues H, Däubener W, Eller SK, Alexander H, Pennino D, Suomela S, Tessa  
313 I, Lybeck E, Baran AM, Darban H, Gangwar RS, Gerstel U, Jahn K, Karisola P, Yan L,  
314 Hansmann B, Katayama S, Meller S, Bylesjö M, Hupé P, Levi-Schaffer F, Greco D, Ranki A,  
315 Schröder JM, Barker J, Kere J, Tsoka S, Lauerma A, Soumelis V, Nestle FO, Homey B,  
316 Andersson B, Alenius H. Microbe-host interplay in atopic dermatitis and psoriasis. *Nat Commun.*  
317 2019 Oct 16;10(1):4703. doi: 10.1038/s41467-019-12253-y. PMID: 31619666; PMCID:  
318 PMC6795799.
- 319 [11] Yalniz FF, Patel KP, Bashir Q, Marin D, Ahmed S, Alousi AM, Chen J, Ciurea SO, Rezvani K,  
320 Popat UR, Shpall EJ, Champlin RE, Oran B. Significance of minimal residual disease  
321 monitoring by real-time quantitative polymerase chain reaction in core binding factor acute  
322 myeloid leukemia for transplantation outcomes. *Cancer.* 2020 May 15;126(10):2183-2192. doi:

- 323 10.1002/cncr.32769. Epub 2020 Feb 26. PMID: 32101640.
- 324 [12] P. Sekula, M.F. Del Greco, C. Pattaro, et al., Mendelian randomization as an approach to  
325 assess causality using observational data, *J. Am. Soc. Nephrol.* 27 (11) (2016) 3253–3265,  
326 <https://doi.org/10.1681/ASN.2016010098>.
- 327 [13] L. Li, Q. Ren, Q. Zheng, et al., Causal associations between gastroesophageal reflux disease  
328 and lung cancer risk: a Mendelian randomization study, *Cancer Med.* 12 (6) (2023) 7552–7559,  
329 <https://doi.org/10.1002/cam4.5498>.
- 330 [14] K. Lee, C.Y. Lim, Mendelian randomization analysis in observational epidemiology, *J Lipid*  
331 *Atheroscler* 8 (2) (2019) 67–77, <https://doi.org/10.12997/jla.2019.8.2.67>.
- 332 [15] E. Birney, Mendelian randomization, *Cold Spring Harb Perspect Med.* 12 (4) (2022) a041302,  
333 <https://doi.org/10.1101/cshperspect.a041302>.
- 334 [16] J.A. de Klerk, J.W.J. Beulens, H.L. Mei, et al., Altered blood gene expression in the obesity-  
335 related type 2 diabetes cluster may be causally involved in lipid metabolism: a Mendelian  
336 randomization study, *Diabetologia* 66 (6) (2023) 1057–1070, [https://doi.org/10.1007/s00125-](https://doi.org/10.1007/s00125-023-05886-8)  
337 [023-05886-8](https://doi.org/10.1007/s00125-023-05886-8).
- 338 [17] Xu L, Li H, Liu B, Han X, Sun H. Systemic Inflammatory Regulators Associated with  
339 Osteoporosis: A Bidirectional Mendelian Randomization Study. *Calcif Tissue Int.* 2024  
340 May;114(5):490-501. doi: 10.1007/s00223-024-01200-9. Epub 2024 Mar 25. PMID: 38528199.
- 341 [18] J. Bowden, M.F. Del Greco, C. Minelli, et al., Assessing the suitability of summary data for two-  
342 sample Mendelian randomization analyses using MR-Egger regression: the role of the I2  
343 statistic, *Int. J. Epidemiol.* 45 (6) (2016) 1961–1974, <https://doi.org/10.1093/ije/dyw220>.
- 344 [19] S. Burgess, S.G. Thompson, Interpreting findings from Mendelian randomization using the MR-  
345 Egger method, *Eur. J. Epidemiol.* 32 (5) (2017) 377–389, [https://doi.org/10.1007/s10654-017-](https://doi.org/10.1007/s10654-017-0255-x)  
346 [0255-x](https://doi.org/10.1007/s10654-017-0255-x).
- 347 [20] J. Bowden, G. Davey Smith, S. Burgess, Mendelian randomization with invalid instruments:  
348 effect estimation and bias detection through Egger regression, *Int. J. Epidemiol.* 44 (2) (2015)  
349 512–525, <https://doi.org/10.1093/ije/dyv080>.
- 350 [21] Fife JD, Cassa CA. Estimating clinical risk in gene regions from population sequencing cohort  
351 data. *Am J Hum Genet.* 2023 Jun 1;110(6):940-949. doi: 10.1016/j.ajhg.2023.05.003. Epub  
352 2023 May 25. PMID: 37236177; PMCID: PMC10257006.
- 353 [22] Fife JD, Cassa CA. Estimating clinical risk in gene regions from population sequencing cohort  
354 data. *Am J Hum Genet.* 2023 Jun 1;110(6):940-949. doi: 10.1016/j.ajhg.2023.05.003. Epub  
355 2023 May 25. PMID: 37236177; PMCID: PMC10257006.
- 356 [23] Chinoy MR. Lung growth and development. *Front Biosci.* 2003 Jan 1;8:d392-415. doi:  
357 10.2741/974. PMID: 12456356.
- 358 [24] Visscher M, Narendran V. The Ontogeny of Skin. *Adv Wound Care (New Rochelle).* 2014 Apr  
359 1;3(4):291-303. doi: 10.1089/wound.2013.0467. PMID: 24761361; PMCID: PMC3985523.
- 360 [25] de Fays C, Carlier FM, Gohy S, Pilette C. Secretory Immunoglobulin A Immunity in Chronic  
361 Obstructive Respiratory Diseases. *Cells.* 2022 Apr 13;11(8):1324. doi: 10.3390/cells11081324.  
362 PMID: 35456002; PMCID: PMC9027823.
- 363 [26] Corthésy B. Multi-faceted functions of secretory IgA at mucosal surfaces. *Front Immunol.* 2013  
364 Jul 12;4:185. doi: 10.3389/fimmu.2013.00185. PMID: 23874333; PMCID: PMC3709412.
- 365 [27] Chen C B, Wu M Y, Ng C Y, et al. Severe cutaneous adverse reactions induced by targeted  
366 anticancer therapies and immunotherapies[J]. *Cancer Manag Res*, 2018,10:1 259-1273.
- 367 [28] Sneddon IB. Cutaneous manifestations of visceral malignancy. *Postgrad Med J.* 1970  
368 Nov;46(541):678-85. doi: 10.1136/pgmj.46.541.678. PMID: 4924274; PMCID: PMC2467095.
- 369 [29] Grainge MJ, West J, Solaymani-Dodaran M, Card TR, Logan RF. The long-term risk of  
370 malignancy following a diagnosis of coeliac disease or dermatitis herpetiformis: a cohort study.  
371 *Aliment Pharmacol Ther.* 2012 Mar;35(6):730-9. doi: 10.1111/j.1365-2036.2012.04998.x. Epub  
372 2012 Jan 30. PMID: 22288441.
- 373 [30] Ugge H, Udumyan R, Carlsson J, Andrén O, Montgomery S, Davidsson S, Fall K. Acne in late  
374 adolescence and risk of prostate cancer. *Int J Cancer.* 2018 Apr 15;142(8):1580-1585. doi:  
375 10.1002/ijc.31192. Epub 2017 Dec 14. PMID: 29205339; PMCID: PMC5838533.
- 376 [31] Murphy JD, Sandler D, White AJ, O'Brien KM. Severe acne and risk of breast cancer. *Breast*  
377 *Cancer Res Treat.* 2019 Sep;177(2):487-495. doi: 10.1007/s10549-019-05302-z. Epub 2019

378 Jun 5. PMID: 31165375; PMCID: PMC6771926.  
 379 [32] Tannenbaum R, Strunk A, Garg A. Association Between Hidradenitis Suppurativa and  
 380 Lymphoma. *JAMA Dermatol.* 2019 May 1;155(5):624-625. doi:  
 381 10.1001/jamadermatol.2018.5230. PMID: 30698627; PMCID: PMC6506877.  
 382 [33] Kohorst JJ, Kimball AB, Davis MD. Systemic associations of hidradenitis suppurativa. *J Am*  
 383 *Acad Dermatol.* 2015 Nov;73(5 Suppl 1):S27-35. doi: 10.1016/j.jaad.2015.07.055. PMID:  
 384 26470611.  
 385 [34] Gau SY, Preclaro IAC, Wei JC, Lee CY, Kuan YH, Hsiao YP, Juang SE, Ma KS. Risk of  
 386 psoriasis in people with hidradenitis suppurativa: A systematic review and meta-analysis. *Front*  
 387 *Immunol.* 2022 Dec 1;13:1033844. doi: 10.3389/fimmu.2022.1033844. PMID: 36532043;  
 388 PMCID: PMC9752046.  
 389 [35] Luo M, Wei B. Novel insights into rosacea's role in cancer risk: A Mendelian randomization  
 390 approach. *Skin Res Technol.* 2024 May;30(5):e13737. doi: 10.1111/srt.13737. PMID:  
 391 38769705; PMCID: PMC11106556.  
 392 [36] Li WQ, Zhang M, Danby FW, Han J, Qureshi AA. Personal history of rosacea and risk of  
 393 incident cancer among women in the US. *Br J Cancer.* 2015 Jul 28;113(3):520-3. doi:  
 394 10.1038/bjc.2015.217. Epub 2015 Jun 23. PMID: 26103573; PMCID: PMC4522627.  
 395

396 **Table 1**

397 The information on skin diseases and non-small cell lung cancer data used in this study, all of  
 398 which can be obtained from the FinnGen database, includes the following:

399 Lung Cancers: Lung Squamous Cell Carcinoma (SCC), Lung Adenocarcinoma (ADC),  
 400 Skin Diseases: Acne (AC), Hidradenitis Suppurativa (HS), Dermatitis Herpetiformis (DH),  
 401 Infective Dermatitis (ID), Localized Scleroderma (LS), Cutaneous Abscess, Furuncle, and  
 402 Carbuncle (CA), Atrophic Disorders of Skin (ADS), Papulosquamous Disorders (PSD), Atopic  
 403 Dermatitis (AD), Urticaria (URT), Rhinophyma (RHN), Acquired Keratosis Palmaris et Plantaris  
 404 (AKD), Pityriasis Lichenoides Chronica (PLC), Pityriasis Rosea (PR), Pyoderma (PYD), Xerosis  
 405 Cutis (XER), Pruritus (PRU), Pemphigus (PEM), Seborrheic Dermatitis (SD), Pityriasis Rubra  
 406 Pilaris (PRP), Lichen Planopilaris (LPP), Acne Conglobata (ACC), Erythema Multiforme (EM),  
 407 Lupus Erythematosus (SLE), Chloasma (CHL), and Pigmented Purpuric Dermatitis (PPD).

Trait	N.cases	N.controls	Populations	Year	Filtering threshold
SCC	1787	345118	European	2024	-
ADC	2064	345118	European	2024	-
AC	3982	432686	European	2024	$P < 5 \times 10^{-8}$
HS	1209	432686	European	2024	$P < 5 \times 10^{-8}$
DH	585	451899	European	2024	$P < 5 \times 10^{-8}$
ID	4195	394476	European	2024	$P < 5 \times 10^{-8}$
LS	450	423041	European	2024	$P < 5 \times 10^{-8}$



CA	10296	426987	European	2024	$P < 5 \times 10^{-8}$
ADS	5037	423041	European	2024	$P < 5 \times 10^{-8}$
PSD	16313	437420	European	2024	$P < 5 \times 10^{-8}$
AD	26905	394476	European	2024	$P < 5 \times 10^{-8}$
URT	12576	438050	European	2024	$P < 5 \times 10^{-8}$
RHN	175	432686	European	2024	$P < 5 \times 10^{-6}$
AKD	137	423041	European	2024	$P < 5 \times 10^{-6}$
PLC	122	437420	European	2024	$P < 5 \times 10^{-6}$
PR	242	437420	European	2024	$P < 5 \times 10^{-6}$
PYD	643	426987	European	2024	$P < 5 \times 10^{-6}$
XER	429	423041	European	2024	$P < 5 \times 10^{-6}$
PRU	3819	394476	European	2024	$P < 5 \times 10^{-6}$
PEM	208	451899	European	2024	$P < 5 \times 10^{-6}$
SD	3382	394476	European	2024	$P < 5 \times 10^{-6}$
PRP	71	437420	European	2024	Insufficient data
LPP	83	432686	European	2024	Insufficient data
ACC	175	432686	European	2024	Insufficient data
EM	754	438050	European	2024	Insufficient data
SLE	777	423041	European	2024	Insufficient data
CHL	127	423041	European	2024	Insufficient data
PPD	289	423041	European	2024	Insufficient data

408 **Table 2**

409 Pleiotropy and heterogeneity test of the MR positive results, including Dermatitis herpetiformis (DH),  
 410 Acne (AC), Hidradenitis suppurativa (HS), and Rhinophyma (RHN). Lung Squamous Cell  
 411 Carcinoma (SCC) and adenocarcinoma of the lung (ADC)

Exposure	Outcome	Heterogeneity		Pleiotropy
		MR Egger Q (P)	IVW Q (P)	Egger intercept (P)
DH	SCC	4.6051 (0.3302)	4.9693 (0.4196)	0.6038
AC		2.0474 (0.5626)	2.9035 (0.5740)	0.4230
HS		1.8801 (0.1703)	10.1380 (0.0062)	0.2834
RHN		0.4662 (0.7920)	1.1637 (0.7617)	0.4915


DH	ADC	4.5910 (0.3318)	4.8008 (0.4406)	0.6909
AC		0.9011 (0.8251)	0.9226 (0.9212)	0.8928
HS		0.0235 (0.8779)	0.2673 (0.8748)	0.7080
RHN		1.9837 (0.3708)	2.1679 (0.5382)	0.7095

412

413 **Table 3**

414 MR analysis results of skin diseases with positive associations and non-small cell lung cancer,  
415 including Dermatitis herpetiformis (DH), Acne (AC), Hidradenitis suppurativa (HS), and  
416 Rhinophyma (RHN), with Lung Squamous Cell Carcinoma (SCC) and adenocarcinoma of the  
417 lung (ADC).






418


419

420 **Figure 1.** The flowchart of the study.



421

422




423

424

425

Figure. 2. Dermatitis herpetiformis and NSCLC ( SCC left ADC right )

426




427

428

429

Figure. 3. Acne and NSCLC ( SCC left ADC right )




430

431

432

Figure. 4. Hidradenitis suppurativa and NSCLC ( SCC left ADC right )

433



434

435

436

Figure. 5. Rhinophyma and NSCLC ( SCC left ADC right )

437



Obtain datasets for skin diseases (exposure) and lung squamous cell carcinoma; lung adenocarcinoma (outcome) from the FinnGen

Select appropriate genetic instrumental variables (GIVs) for skin diseases ( $p < 5 \times 10^{-8}$ ,  $r^2 < 0.001$ , window size=10000kb, minor allele frequency MAF > 0.01; removal of SNPs associated with non-small cell lung cancer. If sufficient SNPs cannot be obtained under the  $p < 5 \times 10^{-8}$  threshold, the standard will be relaxed to  $p < 5 \times 10^{-6}$ ).

medRxiv preprint doi: <https://doi.org/10.1101/2024.09.05.24313092>; this version posted September 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Calculate the F-statistic for each skin disease and remove SNPs with F-values <10.

7 skin diseases still lacked enough instrumental variables

MR Analysis

Heterogeneity tests and sensitivity analyses for genetic instrumental variables with causal relationships.

Removal of potentially pleiotropic SNPs

DH and AC  $\xrightarrow{\text{risk}}$  SCC  
DH, HS and RHN  $\xrightarrow{\text{risk}}$  ADC

15 skin diseases showed no statistically significant association with NSCLC

Figure